{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:58Z","timestamp":1792177738718,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008781.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T00:00:00Z","timestamp":1447804800000}}],"reference-count":46,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008781.pub3","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T16:34:40Z","timestamp":1447864480000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Vigabatrin versus carbamazepine monotherapy for epilepsy"],"prefix":"10.1002","volume":"2015","author":[{"given":"Yousheng","family":"Xiao","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital, Guangxi Medical University; Department of Neurology; No. 22, Shuang Yong Lu Nanning Guangxi China 530021"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Guangxi Medical University; Department of Neurology; No. 22, Shuang Yong Lu Nanning Guangxi China 530021"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Guangxi Medical University; Department of Neurology; No. 22, Shuang Yong Lu Nanning Guangxi China 530021"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Luo","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Guangxi Medical University; Department of Neurology; No. 22, Shuang Yong Lu Nanning Guangxi China 530021"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongye","family":"Luo","sequence":"additional","affiliation":[{"name":"Guangxi Medical University; Department of Epidemiology & Statistics; No. 22, Shuang Yong Lu Nanning Guangxi China 530021"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,18]]},"reference":[{"key":"10.1002\/14651858.CD008781.pub3-BIB0001|cit1","first-page":"33","article-title":"Vigabatrin versus carbamazepine as first line monotherapy in newly diagnosed patients: a double blind randomized parallel group study","volume":"99 Suppl 1","author":"Canger","year":"1997","journal-title":"Bollettino - Lega Italiana Contro L'Epilessia"},{"issue":"9172","key":"10.1002\/14651858.CD008781.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(98)10531-7","article-title":"Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study","volume":"354","author":"Chadwick","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0003|cit3","first-page":"6","article-title":"Vigabatrin (Sabril) as first-line monotherapy in newly diagnosed epilepsy: a double-blind comparison with carbamazepine","volume":"37 Suppl 4","author":"Chadwick","year":"1996","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0004|cit4","first-page":"33","article-title":"Vigabatrin (Sabril) monotherapy and cognitive function in newly diagnosed epilepsy: a double-blind comparison with carbamazepine","volume":"37 Suppl 4","author":"Gisselbrecht","year":"1996","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0005|cit5","first-page":"S60","article-title":"Randomized controlled pilot study of vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy: an interim report","volume":"Suppl 2","author":"Kalviainen","year":"1991","journal-title":"Journal of Child Neurology"},{"issue":"10","key":"10.1002\/14651858.CD008781.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archneur.1995.00540340081016","article-title":"Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study","volume":"52","author":"Kalviainen","year":"1995","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0007|cit7","first-page":"5","article-title":"Visual field defects associated with initial vigabatrin monotherapy as compared with initial carbamazepine monotherapy","volume":"39 Suppl 2","author":"Kalviainen","year":"1998","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0008|cit8","first-page":"S23","article-title":"Prospective neuropsychological and quantitative MRI-follow-up of newly diagnosed patients with epilepsy randomized to either vigabatrin or carbamazepine monotherapy (Abstract)","volume":"4 Suppl 1","author":"Riekkinen","year":"1997","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0009|cit9","first-page":"12","article-title":"Randomized controlled study of the efficacy and safety of vigabatrin versus carbamazepine monotherapy in newly diagnosed epilepsy","volume":"32 Suppl 1","author":"Saukkonen","year":"1991","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0010|cit10","first-page":"47","article-title":"Long-term efficacy and cognitive effects of vigabatrin","volume":"162","author":"Ylinen","year":"1995","journal-title":"Acta Neurologica Scandinavica. Supplementum"},{"issue":"5","key":"10.1002\/14651858.CD008781.pub3-BIB0011|cit11","first-page":"646","article-title":"A comparative study of vigabatrin vs. carbamazepine in monotherapy of newly diagnosed partial seizures in children","volume":"57","author":"Sobaniec","year":"2005","journal-title":"Pharmacological Reports"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0012|cit12","first-page":"58","article-title":"Vigabatrin versus carbamazepine monotherapy in newly diagnosed focal epileptics: a randomised response condition cross-over study","volume":"38 Suppl 3","author":"Regesta","year":"1997","journal-title":"Epilepsia"},{"issue":"Sept","key":"10.1002\/14651858.CD008781.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/S0022-510X(97)85669-9","article-title":"Vigabatrin vs carbamazepine monotherapy in newly diagnosed focal epileptics. A randomized response conditional cross-over study [Abstract]","volume":"150","author":"Regesta","year":"1997","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0014|cit14","first-page":"27","article-title":"Vigbatrin monotherapy in newly diagnosed focal epilepsy","volume":"99 Suppl 1","author":"Regesta","year":"1997","journal-title":"Bollettino - Lega Italiana Contro L'Epilessia"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0015|cit15","first-page":"137","article-title":"Vigabatrin vs carbamazepine in monotherapy in newly diagnosed patients with partial epilepsy: a randomized cross-over study (preliminary data)","volume":"82-83","author":"Tanganelli","year":"1993","journal-title":"Bollettino Lega Italiana Contro L'Epilessia"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0016|cit16","first-page":"64","article-title":"Vigabatrin versus carbamazepine in newly diagnosed epileptic patients: a randomized response conditional cross-over study","volume":"35 Suppl 7","author":"Tanganelli","year":"1994","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0017|cit17","first-page":"S104","article-title":"Vigabatrin versus carbamazepine in newly diagnosed epileptic patients: a randomized response conditional cross-over study","volume":"36 Suppl 3","author":"Tanganelli","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD008781.pub3-BIB0018|cit18","first-page":"4","article-title":"Vigabatrin vs carbamazepine monotherapy in newly diagnosed focal epileptics - a randomized response conditional cross-over study [abstract]","volume":"3","author":"Tanganelli","year":"1996","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD008781.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0920-1211(96)00074-5","article-title":"Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study","volume":"25","author":"Tanganelli","year":"1996","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0020|cit20","first-page":"S103","article-title":"Vigabatrin versus carbamazepine in newly diagnosed partial epilepsy in childhood","volume":"36 Suppl 3","author":"Piattella","year":"1995","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0021|cit21","first-page":"40","article-title":"Open comparative long-term study of VGB [vigabatrin] versus CBZ [carbamazepine] in newly diagnosed partial seizures in children","volume":"39 Suppl 2","author":"Zamponi","year":"1998","journal-title":"Epilepsia"},{"issue":"5","key":"10.1002\/14651858.CD008781.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archneur.56.5.605","article-title":"Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children","volume":"56","author":"Zamponi","year":"1999","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0023|cit23","first-page":"190","article-title":"Rational polytherapy with Sabril (vigabatrin) versus carbamazepine or phenytoin monotherapy in the management of patients with complex partial seizures","volume":"39 Suppl 6","author":"Edwards","year":"1998","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD008781.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0920-1211(98)00124-7","article-title":"Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies","volume":"35","author":"Gobbi","year":"1999","journal-title":"Epilepsy Research"},{"issue":"2","key":"10.1002\/14651858.CD008781.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0920-1211(97)00077-6","article-title":"A comparison of the neuropathological effects of vigabatrin and carbamazepine in patients with newly diagnosed localization-related epilepsy using MR-based cerebral T2 relaxation time measurements","volume":"29","author":"Paesschen","year":"1998","journal-title":"Epilepsy Research"},{"issue":"1","key":"10.1002\/14651858.CD008781.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2009.03.003","article-title":"The descriptive epidemiology of epilepsy - a review","volume":"85","author":"Banerjee","year":"2009","journal-title":"Epilepsy Research"},{"issue":"6","key":"10.1002\/14651858.CD008781.pub3-BIB0027|cit27","first-page":"543","article-title":"Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials","volume":"57","author":"Boutron","year":"2004","journal-title":"Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD008781.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1528-1157.1998.tb01167.x","article-title":"Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy","volume":"39","author":"Commission on Antiepileptic Drugs of the International League Against Epilepsy","year":"1998","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD008781.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.yebeh.2007.12.019","article-title":"The global burden and stigma of epilepsy","volume":"12","author":"Boer","year":"2008","journal-title":"Epilepsy and Behavior"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0030|cit30","first-page":"343","article-title":"Role of the substantia nigra in GABA-mediated anticonvulsant actions","volume":"44","author":"Gale","year":"1986","journal-title":"Advances in Neurology"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Hemming K Maguire MJ Hutton JL Marson AG Vigabatrin for refractory partial epilepsy Cochrane Database of Systematic Reviews 2013","DOI":"10.1002\/14651858.CD007302.pub2"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0032|cit32","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Hopewell S Loudon K Clarke MJ Oxman AD Dickersin K Publication bias in clinical trials due to statistical significance or direction of trial results Cochrane Database of Systematic Reviews (Online) 2009 MR000006","DOI":"10.1002\/14651858.MR000006.pub3"},{"key":"10.1002\/14651858.CD008781.pub3-BIB0034|cit34","unstructured":"Lefebvre C Manheimer E Glanville J\u00a0 Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"issue":"12","key":"10.1002\/14651858.CD008781.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/j.1528-1167.2010.02772.x","article-title":"Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review","volume":"51","author":"Maguire","year":"2010","journal-title":"Epilepsia"},{"issue":"5","key":"10.1002\/14651858.CD008781.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1212\/WNL.46.5.1459","article-title":"Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose","volume":"46","author":"Petroff","year":"1996","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD008781.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Shulz","year":"1995","journal-title":"JAMA"},{"issue":"18","key":"10.1002\/14651858.CD008781.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1517\/14656560903451690","article-title":"Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval","volume":"10","author":"Tolman","year":"2009","journal-title":"Expert Opinion in Pharmacotherapy"},{"issue":"9","key":"10.1002\/14651858.CD008781.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1001\/archneur.61.9.1361","article-title":"Monotherapy in epilepsy: role of the newer antiepileptic drugs","volume":"61","author":"Vazquez","year":"2004","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD008781.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nurt.2006.11.008","article-title":"Vigabatrin","volume":"4","author":"Wheless","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1002\/14651858.CD008781.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1528-1167.2007.01133.x","article-title":"Vigabatrin and epilepsy: lessons learned","volume":"48","author":"Wild","year":"2007","journal-title":"Epilepsia"},{"issue":"22","key":"10.1002\/14651858.CD008781.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time to event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008781.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1528-1167.2008.01988.x","article-title":"Vigabatrin: 2008 Update","volume":"50","author":"Willmore","year":"2009","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD008781.pub3-BIB0044|cit44","first-page":"143","article-title":"Some concerns about adverse event reporting in randomized clinical trials","volume":"66","author":"Yazici","year":"2008","journal-title":"Bulletin of the NYU Hospital for Joint Diseases"},{"issue":"10","key":"10.1002\/14651858.CD008781.pub3-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008781","article-title":"Vigabatrin versus carbamazepine monotherapy for epilepsy","author":"Xiao","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008781.pub3-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008781.pub2","article-title":"Vigabatrin versus carbamazepine monotherapy for epilepsy","author":"Xiao","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008781.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T19:58:26Z","timestamp":1721073506000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008781.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,18]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008781.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,18]]}}}